2023 - Research.com Medicine in United Kingdom Leader Award
2022 - Research.com Best Scientist Award
Peter Jones mainly focuses on Psychiatry, Schizophrenia, Internal medicine, Psychosis and Endocrinology. His studies in Psychiatry integrate themes in fields like Epidemiology, Clinical psychology and Risk factor. His Schizophrenia study combines topics in areas such as Bipolar disorder, Cognition, Neuroscience and Cohort study.
Internal medicine is closely attributed to Placebo in his research. In his study, which falls under the umbrella issue of Psychosis, Ethnic group is strongly linked to Incidence. His work carried out in the field of Cholesterol brings together such families of science as Phytosterol and Food science.
His primary scientific interests are in Internal medicine, Psychiatry, Endocrinology, Psychosis and Schizophrenia. Peter Jones does research in Internal medicine, focusing on Cholesterol specifically. His Cholesterol study frequently intersects with other fields, such as Food science.
The Psychiatry study combines topics in areas such as Cohort study and Clinical psychology. His primary area of study in Endocrinology is in the field of Insulin.
Peter Jones mostly deals with Psychiatry, Psychosis, Internal medicine, Schizophrenia and Clinical psychology. The concepts of his Psychiatry study are interwoven with issues in Cohort study and Cohort. His study connects Young adult and Psychosis.
The various areas that Peter Jones examines in his Internal medicine study include Placebo and Endocrinology. His Schizophrenia study integrates concerns from other disciplines, such as Bipolar disorder, Demography and Cannabis. Peter Jones combines subjects such as Mental health and Anxiety with his study of Clinical psychology.
His primary areas of study are Psychiatry, Internal medicine, Psychosis, Schizophrenia and Cohort. His Psychiatry research incorporates themes from Cohort study and Clinical psychology. His research integrates issues of Placebo and Endocrinology in his study of Internal medicine.
His Psychosis research focuses on Young adult and how it relates to Cognition. His biological study spans a wide range of topics, including Bipolar disorder, First episode, Mood disorders, Major depressive disorder and Ethnic group. Peter Jones works mostly in the field of Cohort, limiting it down to topics relating to Incidence and, in certain cases, Demography and Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review
Theresa H. M. Moore;Stanley Zammit;Stanley Zammit;Anne Lingford-Hughes;Thomas R. E. Barnes.
The Lancet (2007)
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
PS Burge;Pma Calverley;PW Jones;Sally Spencer.
BMJ (2000)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)
Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays.
American Journal of Cardiology (2003)
Preliminary guidelines for empirical research in software engineering
B.A. Kitchenham;S.L. Pfleeger;L.M. Pickard;P.W. Jones.
(2002)
Reduction in Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-Induced Weight Loss in Men: A Randomized, Controlled Trial
Robert Ross;Damon Dagnone;Peter J.H. Jones;Heidi Smith.
Annals of Internal Medicine (2000)
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients: A Systematic Review
Max Marshall;Shon Lewis;Austin Lockwood;Richard Drake.
Archives of General Psychiatry (2005)
CHILD DEVELOPMENTAL RISK-FACTORS FOR ADULT SCHIZOPHRENIA IN THE BRITISH 1946 BIRTH COHORT
P Jones;B Rodgers;R Murray;M Marmot.
The Lancet (1994)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES Study)
Peter Jones;Stephanie Kafonek;Irene Laurora;Donald Hunninghake.
American Journal of Cardiology (1998)
Obstetric Complications and Schizophrenia: Historical and Meta-Analytic Review
Mary Cannon;Peter B. Jones;Robin M. Murray.
American Journal of Psychiatry (2002)
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones;Thomas R. E. Barnes;Linda Davies;Graham Dunn.
Archives of General Psychiatry (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
King's College London
King's College London
King's College London
University of Strathclyde
University of Nottingham
University of Cambridge
University College London
University of Cambridge
Oulu University Hospital
University of Cambridge
Tel Aviv University
Tsinghua University
Institute for the Separation Chemistry in Marcoule
University of Vermont
Argonne National Laboratory
Utrecht University
La Trobe University
Spanish National Research Council
Chinese Academy of Sciences
Academia Sinica
University of Melbourne
École Polytechnique Fédérale de Lausanne
Aarhus University Hospital
University of Massachusetts Amherst
University of Southampton
Innsbruck Medical University